Rapamycin Restores Cerebral Blood Flow in APOE4 Carriers
A four-week course of low-dose rapamycin improved cerebral perfusion in healthy carriers of the high-risk Alzheimer's variant, offering a measurable vascular target for prevention.
Declines in cerebral perfusion often precede clinical memory impairment by more than a decade in people carrying the APOE4 allele. A clinical trial tracking healthy, middle-aged adults with this genetic variant evaluated whether modulating cellular metabolism could protect brain vasculature before structural tissue damage occurs.
Participants completed a four-week regimen of low-dose rapamycin, an mTOR inhibitor originally approved as an immunosuppressant and widely studied in longevity research. Quantitative neuroimaging revealed that four weeks of treatment measurably increased blood flow across vulnerable microvascular networks in the brain, with female carriers demonstrating the most pronounced hemodynamic gains.
Targeting Vascular Decline Before Amyloid Deposition
The finding shifts therapeutic focus from late-stage plaque clearance toward early vascular preservation. Restoring capillary transit time and endothelial function addresses metabolic clearance directly, supporting nutrient delivery to neurons during the decades when prevention remains physiologically viable.
If you carry the APOE4 variant, focus on established vascular health markers—including resting blood pressure, arterial stiffness, and glycemic stability—while clinical trials define precise dosing schedules for preventative pharmaceuticals.
The longer view
One headline rarely tells the story. See how today’s news fits the bigger shifts on AI Trends, or learn to read your own data on How it works.